The obiltoxaximab (anthim) market research report is one of a series of new reports that provides obiltoxaximab (anthim) market statistics, including obiltoxaximab (anthim) industry global market size, regional shares, competitors with a obiltoxaximab (anthim) market share, detailed obiltoxaximab (anthim) market segments, market trends and opportunities, and any further data you may need to thrive in the obiltoxaximab (anthim) industry. This obiltoxaximab (anthim) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The growth in the forecast period can be attributed to rising global bioterrorism threats, growing demand for medical countermeasures, increasing awareness of anthrax exposure risks, increasing government funding for bioterrorism preparedness, rising bioterrorism prevention budgets worldwide. Major trends in the forecast period include partnerships between pharmaceutical companies and governments, advancement of rapid diagnostic tools for anthrax detection, development of newer and more effective monoclonal antibodies, development of biosimilars, advances in targeted delivery systems.
The increasing occurrence of zoonotic diseases is expected to significantly drive the growth of the obiltoxaximab (Anthim) market in the coming years. Zoonotic diseases are infections that spread from animals to humans, either directly or through contact with animal products or vectors such as insects. The rise in zoonotic diseases can be attributed to factors such as greater human-wildlife interaction, urbanization, climate change, and international travel, all of which facilitate the transmission of infections from animals to humans. This growing incidence of zoonotic diseases underscores the need for effective treatments such as obiltoxaximab (Anthim), which targets anthrax, a dangerous zoonotic infection, offering crucial protection amid the increasing frequency of outbreaks. For instance, in December 2023, the World Health Organization reported 684 suspected cases of anthrax across nine out of ten provinces in Zambia, with four confirmed deaths, highlighting the severity of the outbreak. The growing number of zoonotic disease cases will drive the demand for obiltoxaximab (Anthim) in the market.
The expansion of the obiltoxaximab (Anthim) market is also driven by rising healthcare expenditure. Healthcare expenditure refers to the total amount spent on medical services, treatments, hospital care, pharmaceuticals, and other related services. Factors such as an aging population, the rise of chronic diseases, and increased demand for healthcare services are contributing to higher healthcare spending. The growing healthcare expenditure ensures greater access to advanced treatments such as obiltoxaximab (Anthim), as it supports funding for research, procurement, and the deployment of critical therapies needed to manage zoonotic diseases and bioterrorism threats. For example, in May 2024, the Office for National Statistics reported that healthcare expenditure in the UK had increased by 5.6% between 2022 and 2023, marking a significant rise from the 0.9% growth in 2022. This upward trend in healthcare spending is expected to propel the growth of the obiltoxaximab (Anthim) market.
In April 2022, NightHawk Biosciences, a biopharmaceutical company based in the US, acquired Elusys Therapeutics for an undisclosed sum. This acquisition will allow NightHawk to enhance its biodefense portfolio by adding ANTHIM (obiltoxaximab), a treatment for inhalation anthrax. The strategic move aims to leverage existing government contracts and accelerate the development of new therapies for infectious diseases. Elusys Therapeutics, also based in the US, is the manufacturer of obiltoxaximab (Anthim).
The key company operating in the obiltoxaximab (anthim) market is Scorpius Holdings Inc.
North America was the largest region in the obiltoxaximab (anthim) market in 2024. The regions covered in obiltoxaximab (anthim) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the obiltoxaximab (anthim) market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Obiltoxaximab (Anthim) is a monoclonal antibody used to treat inhalational anthrax caused by Bacillus anthracis. It works by binding to the protective antigen component of the anthrax toxin, preventing it from entering cells and causing damage. Obiltoxaximab is typically administered in combination with appropriate antibacterial drugs and is approved for use in both adults and children.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The primary distribution channels for obiltoxaximab (Anthim) include distributors and online pharmacies. Distributors are entities that supply pharmaceutical products from manufacturers to retailers or healthcare providers. Obiltoxaximab is used in the treatment of bioterrorism-related anthrax, including inhalational, cutaneous, and gastrointestinal forms, and is typically administered in hospitals and outpatient clinics.
The obiltoxaximab (anthim) market consists of sales of anthrax therapeutics, infectious disease treatments, emergency biodefense products and intravenous (iv) infusion kits. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The growth in the forecast period can be attributed to rising global bioterrorism threats, growing demand for medical countermeasures, increasing awareness of anthrax exposure risks, increasing government funding for bioterrorism preparedness, rising bioterrorism prevention budgets worldwide. Major trends in the forecast period include partnerships between pharmaceutical companies and governments, advancement of rapid diagnostic tools for anthrax detection, development of newer and more effective monoclonal antibodies, development of biosimilars, advances in targeted delivery systems.
The increasing occurrence of zoonotic diseases is expected to significantly drive the growth of the obiltoxaximab (Anthim) market in the coming years. Zoonotic diseases are infections that spread from animals to humans, either directly or through contact with animal products or vectors such as insects. The rise in zoonotic diseases can be attributed to factors such as greater human-wildlife interaction, urbanization, climate change, and international travel, all of which facilitate the transmission of infections from animals to humans. This growing incidence of zoonotic diseases underscores the need for effective treatments such as obiltoxaximab (Anthim), which targets anthrax, a dangerous zoonotic infection, offering crucial protection amid the increasing frequency of outbreaks. For instance, in December 2023, the World Health Organization reported 684 suspected cases of anthrax across nine out of ten provinces in Zambia, with four confirmed deaths, highlighting the severity of the outbreak. The growing number of zoonotic disease cases will drive the demand for obiltoxaximab (Anthim) in the market.
The expansion of the obiltoxaximab (Anthim) market is also driven by rising healthcare expenditure. Healthcare expenditure refers to the total amount spent on medical services, treatments, hospital care, pharmaceuticals, and other related services. Factors such as an aging population, the rise of chronic diseases, and increased demand for healthcare services are contributing to higher healthcare spending. The growing healthcare expenditure ensures greater access to advanced treatments such as obiltoxaximab (Anthim), as it supports funding for research, procurement, and the deployment of critical therapies needed to manage zoonotic diseases and bioterrorism threats. For example, in May 2024, the Office for National Statistics reported that healthcare expenditure in the UK had increased by 5.6% between 2022 and 2023, marking a significant rise from the 0.9% growth in 2022. This upward trend in healthcare spending is expected to propel the growth of the obiltoxaximab (Anthim) market.
In April 2022, NightHawk Biosciences, a biopharmaceutical company based in the US, acquired Elusys Therapeutics for an undisclosed sum. This acquisition will allow NightHawk to enhance its biodefense portfolio by adding ANTHIM (obiltoxaximab), a treatment for inhalation anthrax. The strategic move aims to leverage existing government contracts and accelerate the development of new therapies for infectious diseases. Elusys Therapeutics, also based in the US, is the manufacturer of obiltoxaximab (Anthim).
The key company operating in the obiltoxaximab (anthim) market is Scorpius Holdings Inc.
North America was the largest region in the obiltoxaximab (anthim) market in 2024. The regions covered in obiltoxaximab (anthim) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the obiltoxaximab (anthim) market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Obiltoxaximab (Anthim) is a monoclonal antibody used to treat inhalational anthrax caused by Bacillus anthracis. It works by binding to the protective antigen component of the anthrax toxin, preventing it from entering cells and causing damage. Obiltoxaximab is typically administered in combination with appropriate antibacterial drugs and is approved for use in both adults and children.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The primary distribution channels for obiltoxaximab (Anthim) include distributors and online pharmacies. Distributors are entities that supply pharmaceutical products from manufacturers to retailers or healthcare providers. Obiltoxaximab is used in the treatment of bioterrorism-related anthrax, including inhalational, cutaneous, and gastrointestinal forms, and is typically administered in hospitals and outpatient clinics.
The obiltoxaximab (anthim) market consists of sales of anthrax therapeutics, infectious disease treatments, emergency biodefense products and intravenous (iv) infusion kits. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Obiltoxaximab (Anthim) Market Characteristics4. Obiltoxaximab (Anthim) Market Trends And Strategies5. Obiltoxaximab (Anthim) Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market7. Global Obiltoxaximab (Anthim) Pricing Analysis & Forecasts30. Global Obiltoxaximab (Anthim) Market Competitive Benchmarking And Dashboard31. Key Mergers And Acquisitions In The Obiltoxaximab (Anthim) Market32. Recent Developments In The Obiltoxaximab (Anthim) Market
3. Obiltoxaximab (Anthim) Market Biologic Drug Characteristics
6. Global Obiltoxaximab (Anthim) Growth Analysis And Strategic Analysis Framework
8. Obiltoxaximab (Anthim) Market Segmentation
9. Global Obiltoxaximab (Anthim) Epidemiology Of Clinical Indications
10. Obiltoxaximab (Anthim) Market Regional And Country Analysis
11. Asia-Pacific Obiltoxaximab (Anthim) Market
12. China Obiltoxaximab (Anthim) Market
13. India Obiltoxaximab (Anthim) Market
14. Japan Obiltoxaximab (Anthim) Market
15. Australia Obiltoxaximab (Anthim) Market
16. South Korea Obiltoxaximab (Anthim) Market
17. Western Europe Obiltoxaximab (Anthim) Market
18. UK Obiltoxaximab (Anthim) Market
19. Germany Obiltoxaximab (Anthim) Market
20. France Obiltoxaximab (Anthim) Market
21. Eastern Europe Obiltoxaximab (Anthim) Market
22. North America Obiltoxaximab (Anthim) Market
23. USA Obiltoxaximab (Anthim) Market
24. Canada Obiltoxaximab (Anthim) Market
25. South America Obiltoxaximab (Anthim) Market
26. Middle East Obiltoxaximab (Anthim) Market
27. Africa Obiltoxaximab (Anthim) Market
28. Obiltoxaximab (Anthim) Market Competitive Landscape And Company Profiles
29. Global Obiltoxaximab (Anthim) Market Pipeline Analysis
33. Obiltoxaximab (Anthim) Market High Potential Countries, Segments and Strategies
34. Appendix
Executive Summary
Obiltoxaximab (Anthim) Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on obiltoxaximab (anthim) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for obiltoxaximab (anthim) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The obiltoxaximab (anthim) market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Distribution Channel: Distributors; Online Pharmacies2) By Application: Bioterrorism Treatment; Inhalational Anthrax; Cutaneous Anthrax; Gastrointestinal Anthrax
3) By End User: Hospitals; Outpatient Clinics
Key Companies Profiled: Scorpius Holdings Inc.
Countries: Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- Scorpius Holdings Inc.
